MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN

Bruce E. Sands  1     Brian G. Feagan  2     Theresa Hunter Gibble  3     Kristina Traxler  3     Nathan Morris  3     Xingyuan Li  3     Stefan Schreiber  4     Vipul Jairath  4     Alessandro Armuzzi  5    
1 Icahn School of Medicine at Mount Sinai, New York, United States
2 Western University, London, Canada
3 Eli Lilly and Company, Indianapolis, United States
4 University Hospital Schleswig-Holstein, Kiel, Germany
5 Humanitas University, Milan, Italy

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing